Gene Dosage Decoded: New Review Maps Path to Precision Therapy for CMT1A

Charcot-Marie-Tooth disease type 1A, the most common inherited demyelinating peripheral neuropathy, has long presented researchers with a paradox: its genetic cause is remarkably uniform, yet its clinical course varies dramatically from patient to patient. A narrative review published in the Egyptian Journal of Medical Human Genetics synthesizes the current evidence on the genetic, molecular and regulatory architecture of CMT1A and maps an increasingly individualized path toward precision molecular therapeutics. The condition stems most often from a recurrent tandem duplication of roughly 1.4 to 1.5 megabases on chromosome 17p12, a segment that encompasses the PMP22 gene, which encodes peripheral myelin protein 22, a small hydrophobic tetraspan membrane glycoprotein produced predominantly by myelinating Schwann cells.

The duplication arises through a well-characterized genomic mechanism. Two highly homologous low-copy repeat elements flanking the region, known as CMT1A-REPs, can misalign during meiosis, promoting non-allelic homologous recombination and an unequal crossover. The duplication-bearing chromosome produces CMT1A, while the reciprocal deletion of the same interval causes hereditary neuropathy with liability to pressure palsies, a distinct disorder marked by recurrent focal neuropathies at sites of mechanical pressure. This reciprocal relationship provides one of the clearest examples of dosage-sensitive disease mechanisms in human neurogenetics: increased PMP22 dosage yields the demyelinating CMT1A phenotype, whereas reduced dosage yields HNPP. Both insufficient and excessive expression disrupt peripheral nerve homeostasis, a relationship the review frames as a functional spectrum from haploinsufficiency to pathological overexpression.

Excess PMP22 does not simply add more myelin protein; it overwhelms the protein-folding and trafficking machinery of myelinating Schwann cells. PMP22 is intrinsically prone to inefficient folding, and even under physiological conditions a substantial fraction of newly synthesized protein fails to reach a properly folded state and is eliminated through endoplasmic reticulum-associated degradation and proteasomal quality-control pathways. The additional copy increases the burden entering the endoplasmic reticulum, accumulating misfolded or improperly trafficked protein and activating ER stress responses and the unfolded protein response, mediated by the PERK, IRE1 and ATF6 signaling branches. Transient activation can be protective, but prolonged PERK signaling may suppress global protein synthesis and alter Schwann-cell differentiation and survival programs. The review notes, however, that the precise relative contribution and temporal activation of individual UPR branches in human CMT1A remain incompletely defined.

Sustained cellular stress interferes with the specialized phenotype of mature myelinating Schwann cells, pushing them toward a stress-associated, pro-dedifferentiation state rather than a complete reversion to an immature identity. One important consequence is disruption of lipid homeostasis: peripheral myelin is highly enriched in cholesterol, phospholipids and specific long-chain fatty acids, and experimental studies in CMT1A models have demonstrated abnormalities in lipid biosynthesis and utilization, suggesting that metabolic dysfunction contributes directly to impaired myelin maintenance rather than being merely a secondary consequence of demyelination. Mitochondrial abnormalities may aggravate this metabolic stress, compromising ATP production and cellular metabolic flexibility, although the precise temporal relationship between ER stress and mitochondrial dysfunction remains unresolved. Because peripheral axons depend on Schwann cells for trophic and metabolic support as well as electrical insulation, altered Schwann-cell metabolism and monocarboxylate transport may leave axons increasingly vulnerable to energetic stress and degeneration.

Although CMT1A is classically classified as a demyelinating neuropathy, the degree of long-term disability is strongly influenced by secondary axonal degeneration, which the review identifies as a primary determinant of irreversible functional impairment in advanced disease. The characteristic onion-bulb formations seen on pathology reflect repeated cycles of Schwann-cell proliferation and attempted remyelination, but axonal degeneration likely results from the combined effects of chronic demyelination, compromised trophic support, metabolic stress and cumulative neuronal injury rather than mechanical compression alone. Limited experimental evidence also suggests that neuromuscular junctions may represent an additional site of functional vulnerability, with abnormalities in distal axonal function and neuromuscular transmission potentially contributing to weakness before extensive motor axon loss becomes apparent. The clinical relevance of this mechanism remains uncertain, but it is therapeutically significant because restoring axonal or neuromuscular junction function could produce measurable benefit even when substantial remyelination is not achieved.

Beyond the coding sequence, the review emphasizes the regulatory architecture governing PMP22 expression. Distal enhancer elements upstream of the gene, characterized by enrichment of active chromatin marks such as H3K27ac and by binding of transcriptional regulators including SOX10, EGR2/KROX20 and TEAD1, contribute to the high transcriptional output required during Schwann-cell myelination. Experimental studies suggest that duplication of regulatory elements surrounding the locus can alter PMP22 expression independently of duplication of the entire gene, and patients with CMT1A-like neuropathy carrying structural duplications involving regulatory regions near PMP22 have been described. PMP22 transcription is also controlled through alternative promoters, P1 and P2, which generate transcripts with distinct 5-prime untranslated regions encoding the same protein; P1 activity is particularly associated with Schwann-cell expression during myelination, while P2 contributes more broadly in non-neural tissues. Epigenetic mechanisms, including DNA methylation, histone modification and chromatin accessibility, add a further layer of potential regulation, though the review stresses that the extent to which epigenetic variation independently determines clinical severity remains uncertain and requires larger longitudinal studies.

That regulatory complexity may help explain why individuals carrying the same recurrent duplication can differ substantially in age at onset, weakness, sensory impairment, foot deformity and progression rate. Among candidate genetic modifiers, SIPA1L2 has received particular attention: analyses in large CMT1A cohorts have identified associations between variation in this gene, which encodes a signaling protein expressed in neural tissues, and measures of disease severity including distal motor function. Experimental observations suggest that modulating SIPA1L2 expression can influence PMP22 expression in Schwann-cell-related systems, but the review urges caution, noting that genetic association does not establish a primary determinant and that subsequent studies have produced relatively modest effects in some models. Variants in LITAF have also been associated with severity differences in selected cohorts, though with less established reproducibility. The review additionally highlights the double-diagnosis phenomenon, in which individuals carrying the PMP22 duplication also harbor pathogenic variants in genes such as GJB1, MPZ or MFN2, producing phenotypes that may reflect two independent genetic disorders rather than modification of a single disease. Distinguishing true modifier alleles from coincidental second diagnoses is essential when interpreting unusually severe cases.

On the therapeutic front, the review details the mixed record of clinical translation. High-dose ascorbic acid and progesterone-related approaches showed encouraging effects in experimental models but failed to produce clinically meaningful benefit in randomized human trials. PXT3003, a fixed-dose combination of baclofen, naltrexone and sorbitol developed through a systems-biology approach, was evaluated in two Phase III trials. In PLEO-CMT, 323 patients with mild-to-moderate CMT1A were randomized to high-dose, low-dose or placebo for up to 15 months; the high-dose formulation was discontinued early because of unexpected crystal formation, and in the modified analysis high-dose PXT3003 was associated with a statistically significant improvement in the primary ONLS endpoint compared with placebo, with a mean difference of minus 0.37 points and a p-value of 0.008. The confirmatory PREMIER trial, testing a single dose corresponding to the high-dose regimen over 15 months, did not meet its primary endpoint, with improvement observed in both treatment and placebo groups rather than the slow deterioration expected from natural history, complicating interpretation and underscoring the challenge of placebo-related effects in a slowly progressive disease.

The most mechanistically direct strategies aim to reduce PMP22 transcript abundance toward a physiological range. Preclinical studies of antisense oligonucleotides and RNA interference, using small interfering RNA and artificial microRNA platforms, have demonstrated that partial reduction of PMP22 expression can improve myelination, nerve conduction and motor phenotypes in CMT1A models. The review stresses that the objective is a normalization window rather than maximal gene silencing, because excessive suppression could theoretically reproduce the consequences of haploinsufficiency and shift the system toward an HNPP-like phenotype. ASOs offer titratable, potentially reversible effects, though repeated administration, tissue distribution, Schwann-cell uptake and long-term tolerability remain open questions. AAV-mediated approaches promise durability from a single administration but create a major limitation: persistent expression of a gene-regulatory construct may be difficult to reverse, and vector distribution, immune responses and the difficulty of delivering to the extensive peripheral nervous system remain obstacles. CRISPR-based disruption of the Schwann-cell-associated P1 promoter has provided proof of concept in experimental models, but delivery, off-target editing, editing efficiency heterogeneity and the irreversibility of genomic modification keep such approaches firmly preclinical. Downstream strategies, including HDAC6 inhibition to restore axonal transport and modulation of skeletal muscle excitability through chloride-channel mechanisms such as ClC-1, remain investigational and are best conceptualized as complementary functional therapies rather than corrections of the underlying molecular defect.

Biomarkers may hold the key to detecting treatment effects in a disease that progresses too slowly for conventional scales. Serum neurofilament light chain, released into biofluids following axonal injury, has been reported at higher concentrations in CMT1A than in healthy individuals and shows associations with measures of disease severity, supporting its use as an exploratory marker of neuroaxonal injury and a potential pharmacodynamic measure in early-phase trials. The review is explicit, however, that NfL is not yet a validated surrogate endpoint: evidence that changes in NfL reliably predict long-term functional outcomes or can support regulatory decision-making remains insufficient, and absolute concentrations vary with age, assay platform and disease stage. Complementary candidates including GFAP, GDF15 and FGF21, along with digital outcome measures such as wearable sensors and smartphone-based gait tracking, similarly require prospective validation. The proposed framework for future trials integrates patient stratification by age, disease duration, baseline function and biological disease activity, follow-up potentially extending to 24 months or beyond, and multidimensional endpoints combining functional scales with longitudinal biomarkers and objectively recorded motor parameters. The central therapeutic objective, the review concludes, remains restoring PMP22 dosage toward a physiologically tolerated range while preserving Schwann-cell and axonal integrity, with success depending on precise control of the magnitude, tissue specificity and duration of intervention.

Subject of Research: Genetic architecture and precision therapeutic strategies for Charcot-Marie-Tooth disease type 1A

Article Title: The genetic architecture and pharmacogenetic landscape of Charcot-Marie-tooth disease type 1 A: a narrative review toward precision molecular therapeutics

Article References: VatanParast, Y. (2026). The genetic architecture and pharmacogenetic landscape of Charcot-Marie-tooth disease type 1 A: a narrative review toward precision molecular therapeutics. Egyptian Journal of Medical Human Genetics, 27(1), Article 88. https://doi.org/10.1186/s43042-026-00920-x

Image Credits: AI Generated

DOI: 10.1186/s43042-026-00920-x

Keywords: CMT1A, PMP22, gene dosage, Schwann cells, peripheral neuropathy, antisense oligonucleotides, gene silencing, neurofilament light chain, genetic modifiers, clinical trials, precision medicine, myelin